Mizuho Securities lowered its price target for Boston Scientific Corp. to $90 from $115 ahead of the company’s Q1 earnings release [1]. Boston Scientific Corp., listed on the U.S. New York Stock Exchange under the ticker BSX, is a leading developer of cardiovascular and peripheral medical devices.
The change comes as investors watch the medical‑device maker’s upcoming results, which could confirm whether recent growth momentum is sustainable — a factor that influences portfolio allocations across the U.S. health‑care sector [2]. Analysts use price targets to gauge fair value, and a downward revision often prompts fund managers to reassess exposure to the stock. The timing of the cut, just days before the earnings announcement, adds weight to market expectations.
Mizuho maintained an Outperform rating while cutting the target, said the firm, and said it was concerned about slowing sales in key product lines and the potential impact of competitive pricing pressures [1]. The firm’s research note said the company’s pipeline remains strong, but short‑term revenue visibility appears muted. Mizuho cut Boston Scientific’s price target to $90, citing growth concerns [1].
Evercore ISI analyst Vijay Kumar reduced his target to $80 from $96 on April 6, reflecting similar worries about market share erosion [3]. Raymond James also trimmed its target to $88, citing the same growth headwinds [4]. Both firms highlighted the importance of upcoming earnings in clarifying whether the slowdown is temporary or structural. Evercore ISI analyst Vijay Kumar lowered his target to $80 on April 6 [3]. The analysts said their revisions reflect a broader caution across the medical‑device sector as hospitals tighten procurement budgets.
Boston Scientific projects Q1 earnings of $0.80 per share, a 6.7% year‑over‑year increase, and expects revenue of roughly $5 billion for the quarter [2]. Management said new product launches and international expansion are expected to drive the modest revenue lift. Boston Scientific forecasts Q1 earnings of $0.80 per share, a 6.7% YoY increase [2]. The company said its cardiac rhythm management and interventional cardiology lines are primary contributors to the earnings growth. Analysts will watch the actual results to gauge whether the guidance translates into sustained momentum.
Collectively, the lower targets suggest analysts are pricing in a more cautious outlook for the company, which could affect its stock performance if the earnings beat expectations or fall short [2]. Investors will likely monitor the earnings release closely, as the results could trigger further revisions from other Wall Street houses. A surprise upside could prompt a rapid price target raise, while a miss may lead to additional downgrades and heightened volatility [2].
“Mizuho cut Boston Scientific’s price target to $90, citing growth concerns.”
Analysts are signaling a more guarded view of Boston Scientific’s near‑term growth, so the stock may see increased volatility around the Q1 earnings release. A beat could quickly lift price targets, while a miss may lead to further downgrades and a broader re‑assessment of the medical‑device sector’s outlook.
